Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
Mathieu, Chantal × Ostenson, Claes-Göran Matthaei, Stephan Reaney, Matthew Krarup, Thure Guerci, Bruno Kiljański, Jacek Salaun-Martin, Carole Sapin, Hélène Theodorakis, Michael #
Springer Healthcare Ltd.
Diabetes Therapy vol:4 issue:2 pages:285-308
CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy; NCT00635492) assessed, as its primary objective, the time to a 'significant treatment change' (defined within this paper) after patients with type 2 diabetes mellitus initiated their first injectable, glucose-lowering therapy [exenatide twice daily (BID) or insulin] in clinical practice in six European countries and evaluated outcomes during the study.